Delivery Order SPE2DB25D2207-SPE2DB26FQPSV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,728.70 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $23,628.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This is a non-set-aside, competitively awarded contract with an ultimate completion date of September 29, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $6,223.32 to AmerisourceBergen Drug Corp on May 30, 2025, for RINVOQ ER 15 mg tablets (30-count units), with final delivery scheduled for June 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract (SPE2DX)...
- The Defense Logistics Agency awarded a delivery order valued at $13,037.95 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on October 23, 2025, with completion scheduled for October 24, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a $26,705.50 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with a firm fixed price structure. This non-competitive delivery order was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose) valued at $6,223.32 on September 19, 2025, with an ultimate completion date of September 22, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The order will be fulfilled at the vendor's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $39,491.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a $28,730.55 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, non-set-aside contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship...
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $26,154.99 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of RINVOQ ER 30 mg tablets (quantity: 30-unit bottles). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB25D2207Indefinite Delivery Contract
- SPE2DB25D2207-SPE2DB26FQPSVDelivery Order
The Defense Logistics Agency awarded a $5,908.17 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for RINVOQ ER 30 mg tablets in quantities of 30 units. This is a non-set-aside competitive award with an ultimate completion date of October 27, 2025, and performance to occur at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999,999,999 comprehensive pharmaceutical supply agreement running through December 2026 that supports global military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's DLA contract vehicle enables supply of a broad range of pharmaceutical products and medical supplies supporting military personnel and veteran healthcare needs. This specific delivery order for RINVOQ ER—a Janus kinase inhibitor used in the treatment of rheumatoid arthritis—represents a routine procurement transaction under the larger strategic pharmaceutical supply framework managed by DLA Troop Support.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.9k | 10/24/25 |